Capsule Summary Slidesets

Share

Program Content

Activities

  • STOMP: Selinexor + Pd
    Phase I/II STOMP Trial: Selinexor, Pomalidomide, and Dexamethasone in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2019

    Expires: December 11, 2020

  • CC-93269 in MM
    First Clinical Study of CC-93269, a BCMA 2+1 T-Cell Engager, in Relapsed/Refractory Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2019

    Expires: December 08, 2020

  • Phase Ib/II CARTITUDE-1
    Phase Ib/II CARTITUDE-1 Study of BCMA-Directed CAR T-Cell Therapy JNJ-4528 in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2019

    Expires: December 13, 2020

  • LEGEND-2: LCAR-B38M in R/R MM
    LEGEND-2 Long-term Follow-up: Phase I Trial of LCAR-B38M CAR T-Cell Therapy in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2019

    Expires: December 11, 2020

  • CASSIOPET: PET/CT in MM
    CASSIOPET: CASSIOPEIA Companion Study Evaluating Prognostic Value of PET/CT in Newly Diagnosed, Transplant-Eligible Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2019

    Expires: December 17, 2020

  • HOVON 143: IxaDaraDex in ND MM
    Phase II HOVON 143 Trial: Interim Analysis of Ixazomib/Daratumumab/Low-Dose Dex in Unfit, Frail Patients With Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 13, 2019

    Expires: December 11, 2020

  • GEM-CESAR: KRd in SMM
    Phase II GEM-CESAR: Carfilzomib/Lenalidomide/Dexamethasone as Curative Regimen for High-Risk Smoldering Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2019

    Expires: December 14, 2020

  • ALCYONE 3-Yr Follow-Up
    ALCYONE 3-Yr Follow-up: Daratumumab Plus VMP vs VMP Alone in Newly Diagnosed, Transplantation-Ineligible Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2019

    Expires: December 13, 2020

  • MASTER: Dara-KRd in NDMM
    MASTER Trial: Response-Adapted Dara-KRd Sequential Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2019

    Expires: December 08, 2020

  • Daratumumab + IRd With Dose-Modified Dex in NDMM
    Phase II Trial of Daratumumab Plus Ixazomib/Lenalidomide/Dose-Modified Dexamethasone in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 18, 2019

    Expires: December 16, 2020

  • Venetoclax + Dex in R/R MM
    Phase I/II Study of Venetoclax + Dexamethasone in Patients With t(11;14) R/R Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2019

    Expires: December 15, 2020

  • CANDOR: KdD in R/R MM
    Phase III CANDOR Trial of Carfilzomib, Dexamethasone ± Daratumumab in Relapsed/Refractory Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2019

    Expires: December 14, 2020

  • Venetoclax/Dara/Dex ± Bortezomib in R/R MM
    Venetoclax/Daratumumab/Dexamethasone ± Bortezomib in Patients With R/R MM: Initial Analysis of a Phase I/II Trial
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • GRIFFIN: VRd ± Dara
    GRIFFIN Update: Phase II Study of Daratumumab + VRd vs VRd Alone for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • GEM-CLARIDEX: Rd ± Clarithromycin
    Phase III GEM-CLARIDEX: Clarithromycin Plus Rd vs Rd Alone in Newly Diagnosed, Transplant-Ineligible Patients with Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company